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ABSTRACT 
0bjective.-To test the hypothesis that the rare, 
often fatal, syndrome of hepatitis-associated aplasia is 
associated with hepatitis C virus infection. 
Design. -Case series. 
Setting. -Tertiary referral centers in the United 
States, Japan, Italy, and Germany. 
Patients. -Twenty-eight patients with onset of 
aplastic anemia within 90 days after seeking medical 
attention for jaundice, or having serum transaminase 
levels 150% or more of normal (hepatitis-associated 
aplasia patients) and three patients who developed 
aplastic anemia following liver transplantation for 
non-A, non-B, hepatitis. 
Outcome Measures. -Presence of hepatitis C in 
serum, bone marrow, and liver samples, detected by the 
polymerase chain reaction; antibody testing; and per- 
centage of activated peripheral cytotozcic T lympho- 
cytes determined by immunophenotyping. 
Results. - Hepatitis ribonucleic acid was present in 
the serum samples of 10 (36%) patients with hepatitis- 
associated aplasia. However, hepatitic C virus viremia 
was associated with transfusions received after the 
onset of aplasia: seven (58%) of 12 patients with 
hepatitis-associated aplasia who had received 21 or 
more units of blood products at the time of serum 
sampling were viremic, compared with only three 
(19%) of 16 patients with hepatitis-associated aplasia 
who had received 20 or less units of blood products 
(P < .05). Hepatitis C virus was not found in blood and 
bone marrow samples of three National Institutes of 
Health case patients tested at the time of diagnosis. 
None of three livers from non-A, non-B hepatitis 
patients who developed aplastic anemia after liver 
transplantation contained hepatitis C virus ribonu- 
cleic acid. Activated CD8+ T lymphocytes were ele- 
vated three- to 20-fold early in the course of hepatitis- 
associated aplasia. 
Conclusions. - Our results implicate a novel, non-A, 
non-B, and non-C agent in both hepatitis-associated 
aplasia and fulminant hepatitis. 
COMMENTS 
Aplastic anemia is a rare but devastating complication 
of hepatitis. The association of hepatitis with aplastic 
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anemia is interesting because it suggests metabolic 
commonalities between the bone marrow and the liver 
that have not been fully appreciated. The agent respon- 
sible for both the hepatitis and the aplastic anemia 
remains unknown but is presumed to be viral. Using the 
technique of reverse transcription combined with the 
polymerase chain reaction (RT-PCR) to detect hepatitis 
C virions, the authors of this paper add to the growing 
evidence that the hepatitis C virus is not responsible for 
the hepatitis or the subsequent aplastic anemia. 
Hepatitis-associated aplastic anemia (H-AA) was first 
reported in the literature in 1955 (1, 2). As methods to  
detect and classify the different hepatitis viruses have 
improved, hepatitis A virus (HAV) and HBV have been 
ruled out as etiological agents of H-AA. The first case of 
H-AA in which HBV and HAV were ruled out as causes 
was reported in 1981 (3). By 1983 a series of 16 patients 
with H-AA had been examined for the presence of HAV 
and HBV (4). In 13 of these 16 cases, neither HAV nor 
HBV was present. The conclusion of this study was that 
some other hepatitis virus - non-A, non-B (NANB) - 
was responsible for the H-AA seen in the majority of 
these patients. 
In 1990, complementary DNA (cDNA) cloning of 
hepatitis C virus (HCV) was reported (51, making 
possible the development of tests for the presence of 
serum antibodies to HCV (6). Shortly thereafter, the 
first experiments to test the hypothesis that HCV is the 
causative agent of H-AA were reported. In a series of 
experiments, investigators examined 19 patients with 
H-AA, 38 patients with aplastic anemia from other 
known causes and 61 cases of aplastic anemia from 
entirely unknown causes (7). Those experiments re- 
vealed that HCV antibodies were present in only 15% of 
H-AA cases, a percentage indistinguishable from that in 
cases of aplastic anemia resulting from other causes. 
The authors concluded that no association between HCV 
and H-AA existed and suggested blood transfusions used 
in the treatment of aplastic anemia accounted for the 
uniform distribution of HCV antibodies among all 
groups of patients with aplastic anemia, regardless of 
the underlying causes. When evaluating this study two 
points should be kept in mind. First, with the first- 
generation assay used in this study, a considerable delay 
of up to several months occurs between infection with 
HCV and the development of HCV antibodies (8). 
Second, immunological abnormalities are seen in pa- 
tients with H-AA that may interfere with an appropriate 
antibody response to HCV infection (9). Therefore the 
absence of antibodies to HCV appears to be an insen- 
sitive indicator for ruling out recent infection with HCV 
in patients with H-AA. 
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The development of RT-PCR has allowed the direct 
measurement of hepatitis C virions in serum and in 
tissues (10). In brief, the virus is pelleted from serum, 
plasma or tissue homogenate; the viral capsid is solubi- 
lized; and the viral RNA is released into solution. The 
RNA is reverse transcribed in vitro, and then, with a 
pair of DNA primers specific for the viral cDNA, the 
viral cDNA is simplified sufficiently for detection on 
an ethidium bromidestained gel. The specificity of 
RT-PCR can be enhanced with the addition of nested 
primers, which are a second set of DNA primers specific 
for the viral genome at an internal site distinct from the 
first set of primers but which are still contained within 
the simplified DNA. Most laboratories that use this 
method with nested primers specific for the 5' end of the 
HCV genome report a sensitivity of 90% to 100% (11). 
The authors of this paper present the analysis of 28 
patients with H-AA, the largest series to date, using 
RT-PCR to detect HCV in the serum and tissues of the 
patients. Their primary hypothesis was that hepatitis C 
is responsible for H-AA. Initially, the authors analyzed 
serum and bone marrow samples from three patients 
with H-AA who were referred to the National Institutes 
of Health. Using RT-PCR, the authors were unable to 
detect HCV RNA in the serum or the bone marrow of 
these three patients. Furthermore, none of these pa- 
tients had antibodies to HCV as determined by the 
second-generation ELISA. After obtaining these neg- 
ative results, the authors analyzed samples from other 
cases of H-AA at the National Institutes of Health and 
samples from cases of H-AA in Germany, Japan and 
Italy. In all, 28 cases of H-AA were analyzed for the 
presence of HCV. Overall, only 10 of the 28 patients had 
HCV RNA detectable in serum; an additional three 
patients had a positive antibody test but a negative 
RT-PCR test. When the cases were stratified by the 
number of transfusions received before the samples for 
HCV testing were obtained, the presence of HCV 
markers appeared to correlate with the number of 
transfusions given to treat the aplastic anemia. Of the 28 
patients, 9 received fewer than five units of blood 
products, and none was positive for HCV antibody or 
HCV RNA. Seven patients received between 8 and 20 
units of blood products before testing; three of these 
seven patients were positive by RT-PCR, and an addi- 
tional two were positive for HCV antibody. Among the 
six patients who had received between 21 and 46 units, 
three were positive by RT-PCR and an additional two 
were positive for HCV antibody. Six patients received 74 
or more units of blood products before testing, and four 
of the six were positive by RT-PCR. On the basis of these 
data, the authors concluded that in the majority of 
patients with H-AA, HCV cannot be implicated as the 
causative agent; instead, HCV infection is acquired as a 
consequence of the treatment of aplastic anemia. 
Almost incidentally, the authors included data on 
peripheral lymphocytes in their original three patients. 
They detected an increase in CD8 + ,DR+ peripheral 
lymphocytes expressed as a percentage of total lympho- 
cytes, and they concluded that this increase in activated 
CD8+ lymphocytes was consistent with a recent viral 
infection. An earlier report indicated that the total 
number of peripheral T lymphocytes is diminished in 
H-AA (9). Therefore it is difficult to draw any conclu- 
sions from the presented data because the authors do 
not express the data as an absolute number of 
CD8 + , DR + lymphocytes and because the sample size is 
so small. Furthermore, an increase in CD8+ lympho- 
cytes, although consistent with recent viral infection, 
can be seen in many other nonviral conditions and does 
not necessarily support a viral cause for the H-AA cases 
being studied. 
The authors used RT-PCR to examine the largest 
assembled group of H-AA patients to date. Experiments 
presented in this paper appear with appropriate con- 
trols, and the main conclusions reached are supported by 
the data. Most convincing is the analysis of the nine 
patients who received fewer than five units of blood 
products. None of these patients was positive for HCV. 
RT-PCR has proved to be a very sensitive method of 
detecting HCV viremia and is presently the only method 
for detecting viremia short of inoculating uninfected 
primates with the serum in question. Of note, the group 
that examined 19 patients with H-AA and 99 patients 
with aplasia of other causes has reexamined their 
samples using RT-PCR (12). They report, in abstract 
form, that only 4 of the 19 samples from H-AA patients 
were positive for HCV RNA and that this rate of 
hepatitis C viremia was no different from that in the 
group with aplastic anemia of other causes. The present 
study, which uses RT-PCR to detect HCV RNA, repre- 
sents an advance in our understanding of H-A4 and 
indicates that we will have to search further for a 
convincing culprit. We may even have to reexamine some 
of our present assumptions about H-AA. The causative 
agent of H-AA may not be a hepatotrophic virus or even 
a virus at all. Perhaps it is time we reconsider toxic 
injury or a nonhepatotrophic virus as a suspect in H-AA. 
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ABSTRACT 
The vectorial nature of hepatocyte receptor-medi- 
ated endocytosis (RME) and its susceptibility to cyto- 
skeletal disruptors has suggested that a polarized 
network of microtubules plays a vital role in directed 
movement during sorting. Using as markers a well- 
known ligand, asialoorosomucoid, and its receptor, we 
have isolated endocytic vesicles that bind directly to 
and interact with stabilized endogenous hepatocyte 
microtubules at specific times during a synchronous, 
experimentally initiated, single wave of RME. Both 
ligand- and receptor-containing vesicles copelleted 
with microtubules in the absence of ATP but did not 
pellet under similar conditions when microtubules 
were not polymerized. When 5 mM ATP was added to 
preparations of microtubule-bound vesicles, ligand- 
containing vesicles were released into the super- 
natant, while receptor-containing vesicles remained 
immobilized on the microtubules. Release of ligand- 
containing vesicles from microtubules was prevented 
by monensin treatment during the endocytic wave. 
Several proteins, including the microtubule motor 
protein cytoplasmic dynein, were present in these 
preparations and were released from microtubule 
pellets by ATP addition concomitantly with ligand. 
These results suggest that receptor domains within the 
endosome can be immobilized by attachment to micro- 
tubules so that, following monensin-sensitive dissoci- 
ation of ligand from receptor, ligand-containing ves- 
icles can be pulled along microtubules away from the 
receptor domains by a motor molecule, such as cyto- 
plasmic dynein, thereby delineating sorting. 
COMMENTS 
The binding of extracellular proteins (and other 
macromolecules) to plasma membrane receptors enables 
eukaryotic cells to internalize selected proteins for their 
specific uses. This process is accomplished through 
receptor-mediated endocytosis (RME), whereby the 
binding of an exogenous protein to a receptor initiates 
receptor clustering within localized regions of the 
plasma membrane, which are usually demarcated by the 
binding of the soluble cytoplasmic protein clathrin to the 
underside of the membrane. The plasma membrane 
then invaginates and pinches off, generating a mem- 
brane-bounded, clathrin-coated vesicle. The clathrin 
then dissociates from the vesicle, generating an en- 
docytic vesicle or “early endosome”; within its lumen is 
the desired protein ligand, and the vesicle membrane 
contains the receptor protein. In this manner, cells can 
import entire proteins from the extracellular envi- 
ronment and still maintain the segregation of exogenous 
proteins from the cytoplasmic space. The ability to 
recognize and internalize macromolecules is an essential 
part of intercellular communication and coordination in 
multicellular organisms. 
Once internalized, the endocytosed macromolecule 
must be directed toward its final destination. In hepa- 
tocytes uptake and sorting of plasma-derived proteins 
can be divided into roughly three pathways (1): toward 
lysosomes for degradation (e.g., asialoglycoproteins, 
lipoproteins, epithelial growth factor and its receptor); 
toward the biliary pole of the hepatocyte for direct 
excretion into bile (IgA and its receptor); and toward 
intracellular regulatory sites (some hormones and 
growth factors). However, this process must be accom- 
plished while maintaining the integrity of the cell 
exterior. In hepatocytes the equivalent of the entire cell 
surface is endocytosed several times each hour. Accord- 
ingly, the endocytosed membrane (and in many cases the 
receptors) are recycled back to the cell surface. 
The first station in endocytic sorting is the dissoci- 
ation of bound protein from the receptor. Endocytic 
vesicles enter into the early endosomal compartment, an 
organelle of considerable structural complexity exhib- 
iting irregularly shaped spherical vesicles attached to 
extended tubular structures that have interconnections. 
Acidification of the lumen of these endocytic structures 
through the action of proton pumps is a basic mech- 
anism for dissociating ligand from the receptor because 
many proteins (such as asialoglycoproteins) bind 
strongly to their receptors at neutral pH outside the cell 
but dissociate at the low pH achieved within endosomes. 
The receptors and membrane to be recycled are then 
segregated from ligand-containing vesicles (“late endo- 
somes”); these vesicles include large transport vesicles 
up to 0.5 pm in diameter and vacuoles with contained 
vesicles (multivesicular bodies), which then move 
toward their final destination. 
The architectural complexity of the endosomal com- 
partment suggests a role for the cytoskeleton, in 
particular microtubules, which now has been well 
documented (2). Microtubules are tubular polymers in 
dynamic equilibrium with dimeric tubulin, a soluble 
cytoplasmic protein composed of a-polypeptide and 
P-polypeptide subunits. The asymmetry in tubulin 
generates asymmetrical polarized microtubules, in 
which the a-oriented end, designated ( + I:, is predomi- 
nantly oriented toward the cell periphery and the 
